One explanation is that dinaciclib targets CDK5, a known regulator of cancer cell motility [59,60], which in our cell lines override PIK-75 effects, even though PI3Ks play key roles in regulating cell motility [61,62]. The gene discussed is CDK5; the disease is cancer.